ArticleMicrobial cell factories2022
Recombinant production of the lantibiotic nisin using Corynebacterium glutamicum in a two-step process.
Article in Microbial cell factories, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Prospects and challenges in using engineered lactic acid bacteria in aquaculture applications.Engineering microbiology · 2026Review
- Bacterial contamination in starch-to-ethanol fermentations: Can bacteriocin-producing Saccharomyces cerevisiae offer a solution?Journal of industrial microbiology & biotechnology · 2026Review
- Detection and quantification of membrane-damaging antimicrobials using pHluorin2-based bacterial biosensors.Frontiers in microbiology · 2026Article
- Nisin or Chitosan Enhance the Antimicrobial Activity of Ceftiofur Against Antibiotic-ResistantPathogens (Basel, Switzerland) · 2025Article
- Production of the Antimicrobial Roseoflavin With Genetically Engineered Corynebacterium glutamicum.Microbial biotechnology · 2025Article
- Secretory Production of Heterologous Antimicrobial Peptides inEngineering in life sciences · 2025Article
- TheCurrent research in microbial sciences · 2025Article
- Antimicrobial peptide production with Corynebacterium glutamicum on lignocellulosic side streams.Biotechnology for biofuels and bioproducts · 2024Article
- Automated workflow for characterization of bacteriocin production in natural producers Lactococcus lactis and Latilactobacillus sakei.Microbial cell factories · 2024Article
- High-throughput detection of potential bacteriocin producers in a large strain library using live fluorescent biosensors.Frontiers in bioengineering and biotechnology · 2024Article
- Use of the mCherry fluorescent protein to optimize the expression of class I lanthipeptides in Escherichia coli.Microbial cell factories · 2023Article
- Protective Cultures in Food Products: From Science to Market.Foods (Basel, Switzerland) · 2023Review
- Identification and Characterization of Corynaridin, a Novel Linaridin from Corynebacterium lactis.Microbiology spectrum · 2023Article
- Optimized recombinant production of the bacteriocin garvicin Q byFrontiers in microbiology · 2023Article
- Improved fluorescent Listeria spp. biosensors for analysis of antimicrobials by flow cytometry.MicrobiologyOpen · 2022Article
- Genome-assisted Identification, Purification, and Characterization of Bacteriocins.Bio-protocol · 2022Article
- Correction to: Recombinant production of the lantibiotic nisin using Corynebacterium glutamicum in a two‑step process.Microbial cell factories · 2022Article
- Quantification of nisin concentration from fluorescence-based antimicrobial activity assay using Bayesian calibration.Biotechnology progressArticle
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundThe bacteriocin nisin is naturally produced by Lactococcus lactis as an inactive prepeptide that is modified posttranslationally resulting in five (methyl-)lanthionine rings characteristic for class Ia bacteriocins. Export and proteolytic cleavage of the leader peptide results in release of active nisin. By targeting the universal peptidoglycan precursor lipid II, nisin has a broad target spectrum including important human pathogens such as Listeria monocytogenes and methicillin-resistant Staphylococcus aureus strains. Industrial nisin production is currently performed using natural producer strains resulting in rather low product purity and limiting its application to preservation of dairy food products.
resultsWe established heterologous nisin production using the biotechnological workhorse organism Corynebacterium glutamicum in a two-step process. We demonstrate successful biosynthesis and export of fully modified prenisin and its activation to mature nisin by a purified, soluble variant of the nisin protease NisP (sNisP) produced in Escherichia coli. Active nisin was detected by a L. lactis sensor strain with strictly nisin-dependent expression of the fluorescent protein mCherry. Following activation by sNisP, supernatants of the recombinant C. glutamicum producer strain cultivated in standard batch fermentations contained at least 1.25 mg/l active nisin.
conclusionsWe demonstrate successful implementation of a two-step process for recombinant production of active nisin with C. glutamicum. This extends the spectrum of bioactive compounds that may be produced using C. glutamicum to a bacteriocin harboring complex posttranslational modifications. Our results provide a basis for further studies to optimize product yields, transfer production to sustainable substrates and purification of pharmaceutical grade nisin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.